Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Iktos
Generative AI for small-molecule drug design and AI-driven retrosynthesis planning.
Iktos develops generative modeling software for drug design. Its Makya platform proposes novel molecules optimized against multiple objectives, while Spaya supports AI-driven retrosynthetic analysis and synthesis planning. Iktos works with pharmaceutical and biotech companies to speed hit-to-lead and lead optimization in medicinal chemistry.
- Headquarters
- Paris, France
- Founded
- 2016
- Deployment options
- cloud, on-premise
- Website
- https://iktos.ai
- https://www.linkedin.com/company/iktos
Categories
AI Use Cases
- Hit Identification & Lead Optimization
Vendor Scorecard
79% — Complete coverage. Coverage score — how completely Atlas documents Iktos across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud, on premise
Pricing Transparency — Documented
SaaS / project based
Implementation & Onboarding — Documented
1–3 months
Organization & Role Fit — Documented
Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery, R&D Leadership
Solution Scope — Documented
ADMET Prediction, Molecular Generation
Company Viability — Partially documented
Private, Founded 2016
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Evidence & Outcomes
Cube Biotech collaboration to design novel Amylin Receptor agonists
Iktos and Cube Biotech announced a strategic collaboration to discover novel small-molecule agonists of the Amylin Receptor, pairing Iktos's AI-driven generative design platform with Cube Biotech's membrane protein production and purification technologies.
press release (Iktos (PR Newswire)) · 2025-01-10 — Partner: Cube Biotech
Pierre Fabre Laboratories oncology drug-discovery collaboration
Pierre Fabre Laboratories and Iktos announced an integrated drug-discovery collaboration to identify and develop novel small-molecule candidates in oncology, with Iktos applying its AI-driven generative design platform alongside Pierre Fabre's medicinal chemistry, biology, and preclinical development.
press release (Iktos (PR Newswire)) · 2026-01-09 — Partner: Pierre Fabre Laboratories
Questions to Ask This Vendor
- How does Makya balance multi-parameter optimization objectives?
- What synthesis routes does Spaya support?
- Can models be deployed on-premise for IP protection?